Shuangcheng pharmaceutical lost 25 million in the first three quarters, what is it?

On October 14, Shuangcheng Pharmaceutical Co., Ltd issued the performance forecast for the first three quarters of 2019 It is estimated that the contribution of non recurring profit and loss to the net profit in the reporting period is about 25.5 million yuan, and the loss in the same period of last year is 32.452 million yuan In the announcement, Shuangcheng pharmaceutical also indicated the main reason for the performance change: with the continuous promotion of the pharmaceutical system reform, influenced by the pharmaceutical industry pattern, procurement rules, adjustment of the medical insurance catalog, competition mechanism, market demand and other factors, the company's own product sales pressure is obvious, and the revenue has declined compared with the same period last year The management attaches great importance to this In order to comply with the industrial trend and the sustainable and healthy development of the company, the company is making every effort to promote the R & D projects, striving for the approval of the projects in progress as soon as possible and achieving the product value as soon as possible through the consistency evaluation Therefore, during the reporting period, R & D investment increased significantly and operating profit decreased year on year It can be seen that, as a result, the share of generic consistency evaluation and innovative drug market has been strengthened, which still has a huge impact on many traditional enterprises, especially those with the main role of generic drugs and insufficient research and development capacity of new drugs And most enterprises, like Shuangcheng pharmaceutical, can't watch the enterprise die They would rather lose money for several years and fight hard They can only praise it This article is reprinted by yaozhi.com The copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.